NCT01337089 2023-04-12
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Jazz Pharmaceuticals
Phase 3 Completed
Clinical Trials
15 trialsNCT01361607 2023-04-12
SPRAY III
Jazz Pharmaceuticals
Phase 3 Completed
NCT01424566 2023-04-12
A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer
Jazz Pharmaceuticals
Phase 3 Completed
NCT02609828 2023-02-16
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
Pfizer
Phase 3 Completed
NCT01964378 2021-07-15
CORAL
Tris Pharma, Inc.
Phase 3 Terminated
NCT02031432 2021-07-15
CORAL XT
Tris Pharma, Inc.
Phase 3 Completed
NCT03031938 2021-06-25
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
Pfizer
Phase 3 Completed
NCT00472303 2019-11-04
A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine
Grünenthal GmbH
Phase 3 Completed
NCT01675622 2018-05-21
Immediate-Release Oxycodone Capsules Study in Cancer Pain
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 3 Completed
NCT01262651 2018-04-23
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
GWPharm
Phase 3 Completed
NCT00352664 2016-05-09
The Effect of Donepezil on Sedation and Other Symptoms
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT00634010 2016-05-09
Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT01384292 2015-06-01
Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain
AstraZeneca
Phase 3 Terminated
NCT00803283 2013-08-12
A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain
Johnson & Johnson Taiwan Ltd
Phase 3 Terminated
NCT01309386 2013-03-13
A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants
Janssen Pharmaceutical K.K.
Phase 3 Completed